Comparative Pharmacology
Head-to-head clinical analysis: ARAMINE versus EPHEDRINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAMINE versus EPHEDRINE SULFATE.
ARAMINE vs EPHEDRINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct-acting sympathomimetic amine that stimulates alpha-adrenergic receptors, causing vasoconstriction and increased blood pressure.
Ephedrine sulfate is a sympathomimetic amine that directly stimulates alpha- and beta-adrenergic receptors and indirectly stimulates norepinephrine release from sympathetic neurons, leading to vasoconstriction, bronchodilation, and increased heart rate and contractility.
Intravenous infusion: 1-10 mg initially, then 0.5-5 mg/hr titrated to blood pressure. Intramuscular or subcutaneous: 2-10 mg every 2 hours as needed.
50 mg orally every 3-4 hours as needed; 25-50 mg intramuscularly or subcutaneously every 3-4 hours; 5-25 mg intravenously slowly every 5-10 minutes as needed, not to exceed 150 mg in 24 hours.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours. Clinical context: Requires continuous infusion for sustained blood pressure support.
Terminal elimination half-life 3-6 hours in adults with normal renal function; prolonged in renal impairment or alkaline urine.
Primarily renal: 85% unchanged drug in urine within 24 hours. Biliary/fecal: <5%.
Renal excretion of unchanged drug (60-70%) and minor metabolites; small amount biliary; pH-dependent; acidic urine enhances elimination.
Category C
Category C
Vasopressor
Vasopressor